Kristen G. Valencia Deray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kristen G. Valencia Deray has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Claire Bocchini
Texas Children's Hospital and Baylor College of Medicine Houston Texas USA
3 shared publications - Monica I. Ardura
Division of Infectious Diseases and Host Defense Program Department of Pediatrics Nationwide Children's Hospital The Ohio State University College of Medicine Columbus Ohio USA
3 shared publications - Tanvi Sharma
Division of Infectious Diseases, Boston Children's Hospital and Harvard Medical School , Boston, Massachusetts
3 shared publications - Betsy C. Herold
Division of Pediatric Infectious Diseases at the Children’s Hospital at Montefiore and the Albert Einstein College Medicine
2 shared publications Claire E. Bocchini
Division of Infectious Diseases Department of Pediatrics Baylor College of Medicine Houston Texas USA
2 shared publications- Flor Muñoz Rivas
Division of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
2 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (8)
Central Nervous System Infections in Pediatric Solid Organ Transplant Recipients
Background: Solid organ transplant (SOT) recipients face an increased risk of central nervous system (CNS) infections due to immunosuppression. The incidence of CNS infections in adult SOT recipients ranges from 0.4% to 10%, while it remains unknown in pediatric SOT recipients. Herein, we describe the incidence, clinical presentation, and outcomes of CNS infections in pediatric SOT recipients. Methods: We conducted a single‐center retrospective cohort study that included 1628 first‐time SOT recipients ≤ 21 years of age from 2003 to 2023. Results: We identified 23 patients with CNS infection representing an incidence of 2.3 per 1000 patient‐years. They occurred in 8/400 (2%) heart; 7/570 (1.2%) liver; 5/220 (2.3%) lung; 2/400 (0.5%) kidney, and 1/38 (2.6%) multi‐organ transplant recipients. Documented symptoms included fever in 15/23 (65%), altered mental status in 7/23 (30%), nausea and emesis in 6/23 (26%), and headache in 6/23 (26%). Neuroimaging was performed in 15/23 (65%) patients with CNS infection; 10/15 (67%) had abnormal findings. Bacterial and fungal infections predominated, each accounting for 8/23 (35%) cases, followed by viral infections in 7/23 (30%) cases. Among patients with CNS infection, all‐cause mortality was observed in 9/23 (39%), while it was 263/1605 (16%) in those without a CNS infection ( p < 0.01). Conclusions: CNS infections in SOT recipients are rare and presentation can be non‐specific, though associated with a high mortality. These findings highlight the importance of maintaining clinical awareness of CNS infection in SOT recipients.
- 17 August 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (8)
Open AccessCentral Nervous System Infections in Pediatric Solid Organ Transplant Recipients
Background: Solid organ transplant (SOT) recipients face an increased risk of central nervous system (CNS) infections due to immunosuppression. The incidence of CNS infections in adult SOT recipients ranges from 0.4% to 10%, while it remains unknown in pediatric SOT recipients. Herein, we describe the incidence, clinical presentation, and outcomes of CNS infections in pediatric SOT recipients. Methods: We conducted a single‐center retrospective cohort study that included 1628 first‐time SOT recipients ≤ 21 years of age from 2003 to 2023. Results: We identified 23 patients with CNS infection representing an incidence of 2.3 per 1000 patient‐years. They occurred in 8/400 (2%) heart; 7/570 (1.2%) liver; 5/220 (2.3%) lung; 2/400 (0.5%) kidney, and 1/38 (2.6%) multi‐organ transplant recipients. Documented symptoms included fever in 15/23 (65%), altered mental status in 7/23 (30%), nausea and emesis in 6/23 (26%), and headache in 6/23 (26%). Neuroimaging was performed in 15/23 (65%) patients with CNS infection; 10/15 (67%) had abnormal findings. Bacterial and fungal infections predominated, each accounting for 8/23 (35%) cases, followed by viral infections in 7/23 (30%) cases. Among patients with CNS infection, all‐cause mortality was observed in 9/23 (39%), while it was 263/1605 (16%) in those without a CNS infection ( p < 0.01). Conclusions: CNS infections in SOT recipients are rare and presentation can be non‐specific, though associated with a high mortality. These findings highlight the importance of maintaining clinical awareness of CNS infection in SOT recipients.
- Open Access
- 28 June 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (7) , ofae353
Multicenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients
Valganciclovir is the only approved antiviral for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation (SOT). Additional approaches may be needed to improve outcomes. A multicenter retrospective study from 2016 to 2019 was conducted of pediatric SOT recipients in whom at least 3 months of valganciclovir prophylaxis was planned. Episodes of CMV DNA in blood (DNAemia), CMV disease, drug-related toxicities, as well as other infections in the first year posttransplant and demographic and clinical data were collected. CMV DNAemia in the first year after prophylaxis or during prophylaxis (breakthrough) was analyzed by multivariate hazard models. Among the 749 patients enrolled, 131 (17.5%) had CMV DNAemia at any time in the first year; 85 (11.4%) had breakthrough DNAemia, and 46 (6.1%) had DNAemia after prophylaxis. CMV disease occurred in 30 (4%). In a multivariate model, liver transplantation compared to kidney or heart, intermediate or high risk based on donor/recipient serologies, neutropenia, and valganciclovir dose modifications attributed to toxicity were associated with increased risk of total and/or breakthrough DNAemia. Bacteremia was also associated with increased hazard ratio for CMV DNAemia. In a separate multivariate analysis, rejection occurred more often in those with breakthrough CMV DNAemia (P = .002); liver transplants, specifically, had increased rejection if CMV DNAemia occurred in the first year (P = .004). These associations may be bidirectional as rejection may contribute to infection risk. CMV DNAemia in the first year posttransplantation occurs despite valganciclovir prophylaxis and is associated with medication toxicity, bacteremia, and rejection. Pediatric studies of newer antivirals, especially in higher-risk subpopulations, appear to be warranted.
- 28 June 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (7) , ofae353
Open AccessMulticenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients
Valganciclovir is the only approved antiviral for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation (SOT). Additional approaches may be needed to improve outcomes. A multicenter retrospective study from 2016 to 2019 was conducted of pediatric SOT recipients in whom at least 3 months of valganciclovir prophylaxis was planned. Episodes of CMV DNA in blood (DNAemia), CMV disease, drug-related toxicities, as well as other infections in the first year posttransplant and demographic and clinical data were collected. CMV DNAemia in the first year after prophylaxis or during prophylaxis (breakthrough) was analyzed by multivariate hazard models. Among the 749 patients enrolled, 131 (17.5%) had CMV DNAemia at any time in the first year; 85 (11.4%) had breakthrough DNAemia, and 46 (6.1%) had DNAemia after prophylaxis. CMV disease occurred in 30 (4%). In a multivariate model, liver transplantation compared to kidney or heart, intermediate or high risk based on donor/recipient serologies, neutropenia, and valganciclovir dose modifications attributed to toxicity were associated with increased risk of total and/or breakthrough DNAemia. Bacteremia was also associated with increased hazard ratio for CMV DNAemia. In a separate multivariate analysis, rejection occurred more often in those with breakthrough CMV DNAemia (P = .002); liver transplants, specifically, had increased rejection if CMV DNAemia occurred in the first year (P = .004). These associations may be bidirectional as rejection may contribute to infection risk. CMV DNAemia in the first year posttransplantation occurs despite valganciclovir prophylaxis and is associated with medication toxicity, bacteremia, and rejection. Pediatric studies of newer antivirals, especially in higher-risk subpopulations, appear to be warranted.
- Open Access
- 1 February 2024
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 13 (Supplement) , S14-S21
Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients
Despite current prophylaxis regimens, cytomegalovirus (CMV) is common in hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) and remains a significant cause of morbidity and mortality. Newer antiviral medications are reshaping the landscape for prevention and treatment of CMV DNAemia, infection, and disease. Letermovir is approved for CMV prevention in adult HCT patients and is attractive due to the absence of marrow suppression seen with ganciclovir/valganciclovir. Letermovir should not be routinely used for CMV treatment due to its low threshold for resistance. Maribavir is approved for the treatment of refractory or resistant CMV disease in HCT and SOT recipients ≥12 years of age, though it has no current role in CMV prevention. More research is needed to fully elucidate the roles, efficacy, and safety of these newer agents in prevention and treatment of CMV in pediatric transplant recipients.
- 1 February 2024
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 13 (Supplement) , S14-S21
Open AccessCurrent and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients
Despite current prophylaxis regimens, cytomegalovirus (CMV) is common in hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) and remains a significant cause of morbidity and mortality. Newer antiviral medications are reshaping the landscape for prevention and treatment of CMV DNAemia, infection, and disease. Letermovir is approved for CMV prevention in adult HCT patients and is attractive due to the absence of marrow suppression seen with ganciclovir/valganciclovir. Letermovir should not be routinely used for CMV treatment due to its low threshold for resistance. Maribavir is approved for the treatment of refractory or resistant CMV disease in HCT and SOT recipients ≥12 years of age, though it has no current role in CMV prevention. More research is needed to fully elucidate the roles, efficacy, and safety of these newer agents in prevention and treatment of CMV in pediatric transplant recipients.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 12
Colonic malakoplakia in a pediatric renal transplant recipient case report
Malakoplakia is a rare, chronic granulomatous disease that mainly affects the genitourinary system of immunocompromised adults. It is caused by a bactericidal deficit in macrophages and, therefore, the treatment includes antimicrobials that reach high concentrations in macrophages. To our knowledge, we present the first case of malakoplakia in a pediatric solid organ transplant recipient. Our patient is a 15-year-old male renal transplant recipient who presented with recurrent diarrhea. Blood, urine, and gastrointestinal pathogen panel testing were positive for enteroaggregative Escherichia coli. A colonoscopy revealed diffuse malakoplakia. He had a complete resolution of symptoms with trimethoprim-sulfamethoxazole therapy. Unfortunately, his malakoplakia recurred after 9 months prompting the transition of therapy to oral gentamicin with subsequent remission. Malakoplakia should be considered in the differential of solid organ transplant recipients with recurrent gastrointestinal infections.
- 1 January 2024
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 12
Open AccessColonic malakoplakia in a pediatric renal transplant recipient case report
Malakoplakia is a rare, chronic granulomatous disease that mainly affects the genitourinary system of immunocompromised adults. It is caused by a bactericidal deficit in macrophages and, therefore, the treatment includes antimicrobials that reach high concentrations in macrophages. To our knowledge, we present the first case of malakoplakia in a pediatric solid organ transplant recipient. Our patient is a 15-year-old male renal transplant recipient who presented with recurrent diarrhea. Blood, urine, and gastrointestinal pathogen panel testing were positive for enteroaggregative Escherichia coli. A colonoscopy revealed diffuse malakoplakia. He had a complete resolution of symptoms with trimethoprim-sulfamethoxazole therapy. Unfortunately, his malakoplakia recurred after 9 months prompting the transition of therapy to oral gentamicin with subsequent remission. Malakoplakia should be considered in the differential of solid organ transplant recipients with recurrent gastrointestinal infections.
- Open Access
- 26 July 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (12) , 1961-1971
Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients
- 26 July 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (12) , 1961-1971
Open AccessBody surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients
- Open Access
- 12 December 2022
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 10
A 6-year-old child with a new diagnosis of perinatal human immunodeficiency virus infection
Perinatal human immunodeficiency virus transmission, while rare in the United States, should be considered in children with a history of recurrent infections, chronic respiratory symptoms and developmental delay. A delayed diagnosis of human immunodeficiency virus in children can lead to significant morbidity and mortality. We present a 6-year-old male who presented for evaluation and management of antibiotic refractory chronic cough and purulent nasal secretions, with a history of recurrent bacterial pneumonias and sinus infections, disseminated varicella zoster, and global developmental delay. He likely had perinatally acquired human immunodeficiency virus. At the time of his human immunodeficiency virus diagnosis, he met the criteria for acquired immunodeficiency syndrome and was ultimately diagnosed with lymphocytic interstitial pneumonia (LIP). Our case illustrates the importance of universal human immunodeficiency virus screening of pregnant women, consideration of human immunodeficiency virus, and the prompt initiation of treatment. We believe this case serves as an important reminder for all medical providers who care for pregnant women and children.
- 12 December 2022
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 10
Open AccessA 6-year-old child with a new diagnosis of perinatal human immunodeficiency virus infection
Perinatal human immunodeficiency virus transmission, while rare in the United States, should be considered in children with a history of recurrent infections, chronic respiratory symptoms and developmental delay. A delayed diagnosis of human immunodeficiency virus in children can lead to significant morbidity and mortality. We present a 6-year-old male who presented for evaluation and management of antibiotic refractory chronic cough and purulent nasal secretions, with a history of recurrent bacterial pneumonias and sinus infections, disseminated varicella zoster, and global developmental delay. He likely had perinatally acquired human immunodeficiency virus. At the time of his human immunodeficiency virus diagnosis, he met the criteria for acquired immunodeficiency syndrome and was ultimately diagnosed with lymphocytic interstitial pneumonia (LIP). Our case illustrates the importance of universal human immunodeficiency virus screening of pregnant women, consideration of human immunodeficiency virus, and the prompt initiation of treatment. We believe this case serves as an important reminder for all medical providers who care for pregnant women and children.
- 27 March 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 26 (5) , e14275
Necrotizing enterovirus myositis in a pediatric renal transplant recipient
Background: Enteroviruses can cause severe infections, including viral myocarditis, meningitis, acute flaccid myelitis, and viral myositis.Methods/Results: We report a 3‐year‐old female renal transplant recipient who presented to a tertiary care hospital with elevated serum liver aminotransferases and subsequently developed proximal muscle pain, weakness, and respiratory distress during the first week of hospitalization. Imaging of the lower extremities revealed diffuse myositis of the proximal thigh and pelvic muscles. A muscle biopsy was obtained and revealed necrotizing myositis with immunostaining positive for enterovirus, consistent with a diagnosis of enterovirus necrotizing myositis. She had complete resolution of symptoms with steroids, intravenous immune globulin, reduced tacrolimus dose, and physical therapy.Conclusions: Enterovirus myositis should be included in the differential diagnosis for necrotizing myositis following renal transplantation in children.
- 27 March 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 26 (5) , e14275
Necrotizing enterovirus myositis in a pediatric renal transplant recipient
Background: Enteroviruses can cause severe infections, including viral myocarditis, meningitis, acute flaccid myelitis, and viral myositis.Methods/Results: We report a 3‐year‐old female renal transplant recipient who presented to a tertiary care hospital with elevated serum liver aminotransferases and subsequently developed proximal muscle pain, weakness, and respiratory distress during the first week of hospitalization. Imaging of the lower extremities revealed diffuse myositis of the proximal thigh and pelvic muscles. A muscle biopsy was obtained and revealed necrotizing myositis with immunostaining positive for enterovirus, consistent with a diagnosis of enterovirus necrotizing myositis. She had complete resolution of symptoms with steroids, intravenous immune globulin, reduced tacrolimus dose, and physical therapy.Conclusions: Enterovirus myositis should be included in the differential diagnosis for necrotizing myositis following renal transplantation in children.
- Open Access
- 1 September 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (1) , 187-198
Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients
- 1 September 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (1) , 187-198
Open AccessEpidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients